Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial on the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.